Europe Electroporation Instruments and Consumables Market

Europe electroporation instruments & consumables market is estimated to grow at a CAGR of 6.8% during the forecast period (2022-2029) to reach a market value of USD YY million by 2029.

Europe has the second largest share in the market owing to the rise in the cases of cancer. According to the Global Cancer Observatory, the number of new incident cancer cases for the year 2018 was 4.2 million and the deaths exceeded 1.94 million in Europe. There are also other factors attributed to the rising incidence of cancer in Europe, i.e., unhealthy lifestyles and inappropriate diet, obesity, and lack of physical activity. Thus, the growing incidence and prevalence of cancer are likely to drive the growth of the market.

In addition, as electroporation continues to gain considerable adoption across Europe due to the increasing approval for the clinical use of electro chemotherapy, market players are likely to focus on tapping into the opportunities across the European Union.

For instance, according to the article published on clinical applications of electrochemotherapy in 2019 by Gregor Serša, mostly used ablative technique is electrochemotherapy. It is a bimodal treatment using cytotoxic drugs bleomycin or cisplatin and electroporation as drug delivery system by using a Cliniporator™ (IGEA, Modena, Italy), which has been designed for electrochemotherapy and is computer controlled. It is approved to use in European Community (EC) countries. There are three types of electrode; selection depends on the size and depth of a tumour. The dose can be delivered using 5 Hz or 5000 Hz.. Its effectiveness is proven on a variety of skin, mucosal and deep seated tumors with complete response rate from 60-90%, depending on the tumor type. The technology is developing fast, and is nowadays practiced in 140 cancer centers throughout Europe.

Increasing number of patients opting for gene therapy in Europe is a major factor driving growth of the electroporation instruments & consumables market. Gene therapy is a leading field in medical science, which promises new treatment development for patients suffering from various diseases.

For instance, Electroporation can now be utilized in vivo for gene transfer, gene therapy, and chemotherapy. Since the late 1980s, a number of in vivo preclinical studies led to the first clinical study that used electroporation to deliver a chemotherapy drug, reported in 1993. Since then, a number of other studies have used EP for electrochemotherapy and gene electrotransfer. The technology has been tested and successfully used in many clinical trials. Electrochemotherapy has been approved for clinical use in several European Union countries and is currently being practiced in more than 100 hospitals throughout Europe.

These genetic markers are associated with complex diseases, therefore it is important to study about the genetic information and its clinical application in designing clinical trials and gene therapy product manufacturing.

According to a data published by the Journal of Gene Medicine, March 2018, till November 2017, an estimated 2,600 gene therapy clinical trials were ongoing, have been completed, or have been approved in 36 countries. Countries where the trials were conducted include the U.K, France, Germany, witzerland, the Netherlands, and others. 

Furthermore, as regulations and guidelines pertaining to the adequate usage of electroporation instruments continue to being published, the demand for electroporation instruments continues to grow.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com